https://doi.org/10.4081/monaldi.2022.1798
Two years progression-free survival under vinorelbine metronomic therapy of a patient with metastatic epithelioid hemangioendothelioma
Submitted: February 8, 2021
Accepted: March 30, 2022
Published: April 1, 2022
Accepted: March 30, 2022
Abstract Views: 1000
PDF: 337
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Epithelioid hemangioendothelioma (EHE) is a very rare vascular tumor, originating from endothelial cells. The etiology of EHE is unknown, yet at the molecular level, different angiogenic stimulators may act as promoters of endothelial cell proliferation. The tumor affects more commonly the lung, the liver and the bones but it can affect any other organ. Due to its heterogeneous presentation and its rarity it is often misdiagnosed. No treatment is proved to be efficient in metastatic EHE and the median survival of patients with metastatic pleural disease is generally poor, less than one year. we report a case of a 57-year-old female with multiple metastatic EHE including pleural, diagnosed by medical thoracoscopy, with a progression-free survival of 24 months with oral vinorelbine as maintenance therapy after combination of cisplatin-vinorelbine. We believe that this therapy might be of value to test in this patient population as it has never been tested before.
Dail DH, Liebow AA, Gmelich JT, et al. Intravascular, bronchiolar, and alveolar tumor of the lung (IVBAT). An analysis of twenty cases of a peculiar sclerosing endothelial tumor. Cancer 1983;51:452-64.
DOI: https://doi.org/10.1002/1097-0142(19830201)51:3<452::AID-CNCR2820510317>3.0.CO;2-M
Sardaro A, Bardoscia L, Petruzzelli MF, et al. Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor. Oncol Rev 2014;8:259.
DOI: https://doi.org/10.4081/oncol.2014.259
Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982;50:970-81.
DOI: https://doi.org/10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z
Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011;140:1312-8.
DOI: https://doi.org/10.1378/chest.11-0039
Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J 1998;12:89-96.
DOI: https://doi.org/10.1183/09031936.98.12010089
Anderson T, Zhang L, Hameed M, et al. Thoracic epithelioid malignant vascular tumors: a clinicopathologic study of 52 cases with emphasis on pathologic grading and molecular studies of WWTR1-CAMTA1 fusions. Am J Surg Pathol 2015;39:132-9.
DOI: https://doi.org/10.1097/PAS.0000000000000346
Lin BT, Colby T, Gown AM, et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases. Am J Surg Pathol 1996;20:1431-9.
DOI: https://doi.org/10.1097/00000478-199612000-00001
Stacchiotti S, Provenzano S, Dagrada G, et al. Sirolimus in advanced epithelioid hemangioendothelioma: A retrospective case-series analysis from the Italian Rare Cancer Network Database. Ann Surg Oncol 2016;23:2735-44.
DOI: https://doi.org/10.1245/s10434-016-5331-z
Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 2008;97:321-9.
DOI: https://doi.org/10.1002/jso.20973
Gaur S, Torabi A, O'Neill TJ. Activity of angiogenesis inhibitors in metastatic epithelioid hemangioendothelioma: a case report. Cancer Biol Med 2012;9:133-6.
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
DOI: https://doi.org/10.1016/S0140-6736(12)60651-5
Lee YJ, Chung MJ, Jeong KC, et al. Pleural epithelioid hemangioendothelioma. Yonsei Med J 2008;49:1036-40.
DOI: https://doi.org/10.3349/ymj.2008.49.6.1036
Hatzimichael E, Briasoulis E. Metronomic chemotherapy beyond misconceptions. Haematologica 2013;98:e145.
DOI: https://doi.org/10.3324/haematol.2013.096917
Mavroeidis L, Sheldon H, Briasoulis E, et al. Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol 2015;47:455-64.
DOI: https://doi.org/10.3892/ijo.2015.3059
Froudarakis ME, Briasoulis E. Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient. BMC Res Notes 2010;3:195.
DOI: https://doi.org/10.1186/1756-0500-3-195
Briasoulis E, Aravantinos G, Kouvatseas G, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013;13:263.
DOI: https://doi.org/10.1186/1471-2407-13-263
Pujol JL, Coffy A, Camerini A, et al. An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. PLoS One 2019;14:e0220988.
DOI: https://doi.org/10.1371/journal.pone.0220988
How to Cite
Anevlavis, Stavros, Georgia Karpathiou, Paschalis Ntolios, and Marios E. Froudarakis. 2022. “Two Years Progression-Free Survival under Vinorelbine Metronomic Therapy of a Patient With Metastatic Epithelioid Hemangioendothelioma”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.1798.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- N. Ambrosino, M. Di Giorgio, A. Di Paco, The patients with severe Chronic Obstructive Pulmonary Disease and chronic respiratory insufficiency , Monaldi Archives for Chest Disease: Vol. 67 No. 3 (2007): Pulmonary series
- Mario Petretta, Wanda Acampa, Emilia Zampella, Roberta Assante, Maria Piera Petretta, Renato Cuocolo, Irma Fabiani, Giuseppe Luca Della Ratta, Pasquale Perrone-Filardi, Alberto Cuocolo, Imaging techniques for assessment of coronary flow reserve , Monaldi Archives for Chest Disease: Vol. 76 No. 4 (2011): Cardiac series
- Lorenzo Palleschi, Eleonora Nunziata, Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- K. Malagari, S. Papiris, Fibrosing mediastinitis causing rapidly progressive dyspnea, pulmonary edema and death in a 16 yr old male , Monaldi Archives for Chest Disease: Vol. 61 No. 2 (2004): Pulmonary series
- Bruno Sposato, Significant gas-exchange improvements reported after roflumilast in two cases of severe COPD , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
- Giovanni Luca Botto, Carlo Piemontese, Giovanni Russo, Rhythm-control vs rate-control in the elderly: When to do it and which drug to prefer? , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Maddalena Modica, Roberta Carabalona, Rosa Spezzaferri, Monica Tavanelli, A. Torri, Vittorino Ripamonti, Paolo Castiglioni, Renata De Maria, Maurizio Ferratini, Psychological profiles derived by cluster analysis of Minnesota Multiphasic Personality Inventory and long term clinical outcome after coronary artery by pass grafting , Monaldi Archives for Chest Disease: Vol. 78 No. 1 (2012): Cardiac series
- C. Ortolani, F. Agostinis, S. Amoroso, R. Ariano, A. Barbato, M. Bassi, G. Cadario, P. Campi, F. Cardinale, G. Ciprandi, R. D’Anneo, M. Di Gioacchino, V. Di Rienzo, A. Fiocchi, M. Galimberti, E. Galli, M. Giovannini, C. Incorvaia, S. La Grutta, C. Lombardi, F. Marcucci, G. Marseglia, M. Minelli, A. Musarra, E. Nettis, E. Novembre, G. Pajno, G. Patriarca, F. Pezzuto, P. Piras, S. Pucci, A. Romano, C. Romano, O. Quercia, G. Scala, D. Schiavino, G. Sforza, M. Tosca, S. Tripodi, F. Frati, Practice parameters for sublingual immunotherapy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- L. Casali, G. Pinchi, E. Puxeddu, Doping and Respiratory System , Monaldi Archives for Chest Disease: Vol. 67 No. 1 (2007): Pulmonary series
- E. Garattini, D. Bilton, G. Cremona, M. Hodson, Adult cystic fibrosis care in the 21st century , Monaldi Archives for Chest Disease: Vol. 75 No. 3 (2011): Pulmonary series
<< < 54 55 56 57 58 59 60 61 62 63 > >>
You may also start an advanced similarity search for this article.
